Ipilimumab, a Promising Immunotherapy with Increased Overall Survival in Metastatic Melanoma?
Malignant melanoma (MM) is one of the most aggressive skin cancer. The therapeutic options remain limited for advanced MM, and those directed to the neoplastic cells have not brought major survival advantage so far. Immunotherapy is another targeted option. Ipilimumab, a monoclonal antibody directed...
Saved in:
Main Authors: | Gérald E. Piérard, François Aubin, Philippe Humbert |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2012-01-01
|
Series: | Dermatology Research and Practice |
Online Access: | http://dx.doi.org/10.1155/2012/182157 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Retrospective Analysis of Rechallenge with Ipilimumab in Patients with Metastatic Melanoma
by: A. A. Formozo, et al.
Published: (2021-01-01) -
Ipilimumab: A First-in-Class T-Cell Potentiator for Metastatic Melanoma
by: Bartosz Chmielowski
Published: (2013-01-01) -
Nivolumab and Ipilimumab Combination Immunotherapy for Patients with Metastatic Collecting Duct Carcinoma
by: Tetsuya Danno, et al.
Published: (2021-01-01) -
Progress in immunotherapy for brain metastatic melanoma
by: Shicheng Zheng, et al.
Published: (2025-01-01) -
Neurocognitive Function, Psychosocial Outcome, and Health-Related Quality of Life of the First-Generation Metastatic Melanoma Survivors Treated with Ipilimumab
by: Anne Rogiers, et al.
Published: (2020-01-01)